Methylation of TMEFF2 Gene in Tissue and Serum DNA from Patients with Non-Small Cell Lung Cancer
분야
의약학 > 내과학
저자
서혜원 , ( Su Man Lee ) , ( Seung Soo Yoo ) , ( Shin Yup Lee ) , ( Jaehee Lee ) , ( Seung Ick Cha ) , ( Chang Ho Kim ) , ( Dong Sun Kim ) , ( Jae Yong Park )
발행기관
대한결핵 및 호흡기학회
간행물정보
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 240(총1페이지)
파일형식
0y909982.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Lung cancer remains a global health problem with a high mortality rate. CpG island methylation is a common aberration frequently associated with gene silencing in multiple tumor types, emerging as a highly promising biomarker. The trans-membrane protein with a single EGF-like and two follistatin domains (TMEFF2) is epigenetically silenced in numerous tumor types, suggesting a potential role as a potential tumor suppressor. However, the role of TMEFF2 in lung cancer remains to be fully elucidated. We explored the methylation status of the TMEFF2 gene in 139 patients with non-small cell lung cancer (NSCLC) and the feasibility of detecting circulating methylated DNA as a screening tool for NSCLC using methylation-specific PCR (MSP). TMEFF2 methylation in tumor tissues was found in 73 of the 139 NSCLCs (52.5%) and was related to gene expression. In adenocarcinomas, TMEFF2 methylation was significantly more frequent in tumors without EGFR mutation than those with EGFR mutation (adjusted hazard ratio=, 95% confidence interval=, P=0.002). In addition, the frequency of TMEFF2 methylation was also higher in females and never-smokers than in males and smokers with borderline significance (65.8% vs 47.8%, p=0.06; 65.7% vs 48.1%, p=0.07). Furthermore, TMEFF2 methylation was exclusively detected in the serum of NSCLC patients at a frequency of 9.2% (29/316). These findings suggest that the methylation-associated down-regulation of the TMEFF2 gene may be involved in early lung tumorigenesis and TMEFF2 methylation can serve as a specific blood-based biomarker for NSCLC.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.